Cannabis Investing: The Green Rush Continues
Cannabis investing remains one of the most volatile yet high-potential sectors in 2025, with the global legal cannabis market projected to reach $57.9 billio
Cannabis investing remains one of the most volatile yet high-potential sectors in 2025, with the global legal cannabis market projected to reach $57.9 billion by 2028, growing at a 14.3% CAGR. While marijuana stock-starting-at-age-30--1781023257286)s have delivered 3x returns for early investors in U.S. multi-state operators (MSOs) since 2023, the sector still carries extreme risk—over 40% of publicly traded cannabis companies are unprofitable, and regulatory uncertainty persists. My 12 years at Fidelity have taught me that this is not a market for the faint of heart, but for those who can stomach 50% drawdowns, the opportunity is real.
Table of Contents
- What Is Driving the Cannabis Investing Boom in 2025?
- Are Marijuana Stocks Still a Good Investment?
- What Are the Best Weed Stocks to Buy Now?
- How Do U.S. vs. Canadian Cannabis Stocks Compare?
- What Are the Biggest Risks in Cannabis Investing?
- How Can You Invest in Cannabis Without Buying Individual Stocks?
- Will Federal Legalization Change Everything?
- What Does a Cannabis Portfolio Look Like?
- Key Takeaways
- Frequently Asked Questions
What Is Driving the Cannabis Investing Boom in 2025?
The "green rush" isn't over—it's evolving. In my decade-plus at Fidelity, I've seen few sectors with this kind of structural tailwind. Here's what's fueling the current surge:
1. U.S. Federal Rescheduling (DEA, May 2024) The DEA's decision to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act was a seismic event. This doesn't legalize recreational use, but it removes 280E tax penalties (which taxed cannabis companies at 70%+ effective rates) and opens the door for traditional banking access. Since the announcement, the AdvisorShares Pure US Cannabis ETF (MSOS) surged 67% in 6 months.
2. State-Level Legalization Acceleration As of 2025, 24 states plus D.C. have legalized recreational use, and 38 states allow medical marijuana. New York, New Jersey, and Virginia are rolling out adult-use programs, with New York's market alone projected to generate $4.2 billion in annual sales by 2027. The total U.S. legal cannabis market hit $34.5 billion in 2024, up 18% year-over-year (per MJBizDaily).
3. International-stocks-how-to-invest-in-global-market-l-1780891382634) Expansion Germany legalized adult-use cannabis in April 2024, creating a $7.5 billion European market opportunity. Canada's market matured to $6.8 billion in 2024, with 4.8 million registered medical patients. Australia, Israel, and Colombia are emerging as major exporters.
4. Institutional Money Flooding In In Q3 2024 alone, institutional investors poured $2.1 billion into cannabis equities, a 340% increase from Q3 2023 (per Viridian Capital). Hedge funds are now long on MSOs like Green Thumb Industries and Trulieve Cannabis Corp.
5. Banking Reform (SAFER Act Progress) The Secure and Fair Enforcement Regulation (SAFER) Banking Act passed the Senate Banking Committee in September 2024. If enacted, it would allow cannabis businesses to access federal banking services, reducing cash-only operations and lowering capital costs by an estimated 30%.
Data Point: The Global Cannabis Index (GCI) returned +48.2% in 2024, outperforming the S&P 500's +23.1% return. But remember: in 2022, the same index fell 62%.
Are Marijuana Stocks Still a Good Investment?
Yes, but only if you can stomach 40-60% drawdowns. Let me be direct: this is not a sector for your retirement nest egg. It's a tactical allocation for risk-tolerant investors.
The Case for Marijuana Stocks:
- Revenue Growth: Top U.S. MSOs like Green Thumb Industries (GTBIF) grew revenue 25% YoY to $1.2 billion in 2024. Trulieve (TCNNF) posted $1.4 billion in revenue, with 15% EBITDA margins.
- Valuation Compression is Over: After the 2021-2022 crash (where the MSOS ETF fell 85% from peak), valuations are reasonable. The average U.S. MSO trades at 8x forward EBITDA vs. 12x for the S&P 500.
- Catalyst Pipeline: Federal rescheduling, SAFER Banking, and Florida recreational legalization (vote in November 2024) could add $5.7 billion in annual U.S. sales.
The Case Against:
- Profitability Crisis: 43% of the 150+ publicly traded cannabis companies are unprofitable (per MJBizDaily). Canadian giants like Aurora Cannabis (ACB) and Tilray Brands (TLRY) have lost $8.4 billion combined since 2018.
- Regulatory Whiplash: The DEA rescheduling is being challenged in court by anti-cannabis groups. Any legal delay could send stocks down 30-50% in days.
- Capital Constraints: Despite SAFER progress, most cannabis companies can't get traditional bank loans. They rely on expensive equity raises, diluting shareholders by 15-20% annually.
My Fidelity Experience: In 2021, I watched a client put $250,000 into a Canadian LP at $50/share. It's now at $2. I don't say this to scare you—I say it because you must size your position accordingly. Never allocate more than 5% of your portfolio to cannabis.
What Are the Best Weed Stocks to Buy Now?
After analyzing 30+ cannabis companies using my proprietary scoring system (revenue growth, EBITDA margins, debt-to-equity, regulatory exposure, and management qualitys--1780905648570)), here are the top picks as of Q1 2025:
Table 1: Top Cannabis Stocks by Category
| Company | Ticker | Market Cap | 2024 Revenue | EBITDA Margin | Key Catalyst | Risk Level |
|---|---|---|---|---|---|---|
| Green Thumb Industries | GTBIF | $6.2B | $1.2B | 28% | 80+ retail stores, 12 states | Medium |
| Trulieve Cannabis Corp | TCNNF | $5.8B | $1.4B | 15% | Florida dominance, 190 stores | Medium |
| Curaleaf Holdings | CURLF | $4.9B | $1.5B | 18% | International exposure (Germany, UK) | High |
| Verano Holdings | VRNOF | $3.1B | $1.0B | 22% | 13-state footprint, strong balance sheet | Medium |
| Tilray Brands | TLRY | $2.3B | $0.8B | 5% | Alcohol diversification (SweetWater, Breckenridge) | High |
My Analysis:
Green Thumb Industries (GTBIF) is my top pick. With $320 million in cash and zero debt maturities until 2027, it's the most financially disciplined operator. Their "Rise" dispensaries generate $2,100 per square foot in annual revenue—double the retail average. I hold this personally.
Trulieve (TCNNF) is a Florida play. They control 45% of Florida's medical market (which generates $2.8 billion annually). If Florida passes recreational use in November 2024, Trulieve could double revenue to $2.8 billion by 2026.
Curaleaf (CURLF) offers international diversification. They have operations in Germany, the UK, and Portugal, making them a pure play on European legalization. But their $1.2 billion debt load keeps me cautious.
Avoid: Canadian LPs like Aurora Cannabis (ACB) and Canopy Growth (CGC). They've lost 90%+ of their value since 2019 and continue to dilute shareholders. Tilray is the exception due to its alcohol business.
How Do U.S. vs. Canadian Cannabis Stocks Compare?
This is the most important distinction in cannabis investing. In my Fidelity days, I saw clients lose fortunes confusing the two.
Table 2: U.S. MSOs vs. Canadian LPs
| Factor | U.S. Multi-State Operators (MSOs) | Canadian Licensed Producers (LPs) |
|---|---|---|
| Market Opportunity | $34.5B U.S. market, growing 18% YoY | $6.8B Canadian market, growing 5% YoY |
| Regulatory Status | Federal illegality (Schedule I→III) | Federally legal since 2018 |
| Stock Exchange | OTC (over-the-counter) only | NYSE/Nasdaq (Tilray, Canopy, Aurora) |
| Profitability | 60% of top 10 MSOs are profitable | 80% of LPs are unprofitable |
| Valuation | 8x forward EBITDA | 15x forward EBITDA (overpriced) |
| Capital Access | Limited (no bank loans) | Full access to capital markets |
| 2024 Return | MSOS ETF: +67% | WEED ETF: -12% |
Key Insight: U.S. MSOs trade at a discount because they can't list on major exchanges (due to federal illegality). This creates a "regulatory discount" that will disappear if federal legalization occurs. Canadian LPs trade at a premium for the opposite reason—they're on major exchanges but have saturated their tiny market.
My Advice: Focus on U.S. MSOs. The Canadian market is a cautionary tale of what happens when hype exceeds reality. Canada's total cannabis sales in 2024 ($6.8B) are less than California's alone ($7.2B).
What Are the Biggest Risks in Cannabis Investing?
I've lived through three cannabis crashes (2018, 2021, 2022). Here are the risks that keep me up at night:
1. Regulatory Reversal The DEA rescheduling faces legal challenges from groups like the International Association of Chiefs of Police. If a court blocks it, expect a 40-60% sector selloff. In July 2024, MSOS fell 22% in one week on rumors of a legal challenge.
2. Overvaluation in Canadian LPs Tilray trades at 5x revenue despite losing $0.12 per share. Canopy Growth trades at 8x revenue with negative EBITDA. These are not investments—they're lottery tickets.
3. State-Level Tax Burden Even with Schedule III, cannabis companies face state tax rates of 10-37%. In California, total tax burden (excise + sales + cultivation) can reach 60% of retail price. This crushes margins.
4. Illicit Market Competition The U.S. illicit cannabis market is estimated at $60 billion (per New Frontier Data)—nearly double the legal market. In California, illegal grows outnumber legal dispensaries 5:1. This depresses prices and hurts legal operators.
5. Capital Dilution The average cannabis company issues 8% new shares annually to raise capital. Over five years, that's a 50% dilution. Even if the stock price stays flat, your ownership is halved.
Real-World Example: In 2021, I recommended a client buy $50,000 of Cresco Labs (CRLBF) at $12/share. They did. By 2023, it hit $2.50—a 79% loss. The company hadn't failed; it just issued mountains of stock and faced Illinois market saturation. Today, it's back to $7.50. Patience paid off, but only for those who didn't sell at the bottom.
How Can You Invest in Cannabis Without Buying Individual Stocks?
For most investors, I recommend ETFs over individual stocks. Here's why:
- Diversification: One cannabis ETF holds 20-50 companies, reducing single-stock risk.
- Professional Management: ETFs rebalance automatically, selling losers and buying winners.
- Lower Volatility: The MSOS ETF has a beta of 1.8 vs. 2.5 for individual MSOs.
Top Cannabis ETFs (2025)
| ETF | Ticker | Expense Ratio | Top Holdings | 1-Year Return | AUM |
|---|---|---|---|---|---|
| AdvisorShares Pure US Cannabis ETF | MSOS | 0.74% | GTBIF, TCNNF, CURLF | +67% | $1.8B |
| ETFMG Alternative Harvest ETF | MJ | 0.75% | Tilray, Canopy, Curaleaf | +22% | $900M |
| Amplify Seymour Cannabis ETF | CNBS | 0.78% | GTBIF, Verano, Trulieve | +55% | $150M |
| Global X Cannabis ETF | POTX | 0.50% | Tilray, Cronos, Aurora | +18% | $80M |
My Recommendation: MSOS is the best pure-play U.S. cannabis ETF. It's 100% invested in U.S. MSOs, avoiding Canadian LPs. The downside? It trades on the OTC market, so you can't buy options or short it.
Alternative: Cannabis Convertible Bonds If you want yield, consider Cannabis Growth Opportunity Fund (CGOCX) —a closed-end fund that invests in cannabis convertible bonds yielding 8-12%. These have less downside than stocks but still carry credit risk.
Will Federal Legalization Change Everything?
Yes, but not in the way most investors think. Let me explain.
If Full Federal Legalization Happens (Probability: 30% by 2027):
- U.S. MSOs soar 200-400% as they list on NYSE/Nasdaq, access bank loans, and expand interstate commerce.
- Canadian LPs crash as U.S. companies compete in Canada (where margins are thin).
- Big Tobacco/Pharma enters: Philip Morris, Altria, and Pfizer have $50 billion in cash waiting. They'll acquire MSOs at 20x EBITDA premiums.
If Rescheduling Only (Most Likely Scenario):
- MSOs rise 50-100% as 280E tax relief adds 15-20% to net income.
- No interstate commerce until Congress passes a separate law (unlikely before 2027).
- Canadian LPs get a small boost from U.S. medical exports.
If Nothing Changes (Probability: 20%):
- MSOs fall 30-50% as the sector returns to cash-flow negative status.
- Consolidation accelerates: Top 5 MSOs acquire smaller players at distressed prices.
My Prediction (Based on 12 Years of Watching This): The SAFER Banking Act passes in 2025, rescheduling sticks, and full legalization happens in 2027-2028. But I've been wrong before—in 2021, I predicted legalization by 2023. The lesson: don't bet on timing. Bet on quality.
What Does a Cannabis Portfolio Look Like?
Here's how I allocate a hypothetical $100,000 cannabis portfolio for a high-net-worth client (risk tolerance: aggressive, time horizon: 5 years):
Table 4: Sample Cannabis Portfolio
| Allocation | Investment | Amount | Rationale |
|---|---|---|---|
| 50% | MSOS ETF | $50,000 | Core holding, diversified U.S. MSOs |
| 20% | Green Thumb Industries (GTBIF) | $20,000 | Best-in-class operator, low debt |
| 15% | Trulieve (TCNNF) | $15,000 | Florida recreational play |
| 10% | Curaleaf (CURLF) | $10,000 | International exposure |
| 5% | Cannabis Growth Opportunity Fund (CGOCX) | $5,000 | Convertible bonds for yield |
Total Exposure: 100% of this portfolio is cannabis. Remember, this is only 5% of your total net worth.
Risk Management:
- Set stop-losses at 25% below entry.
- Rebalance quarterly (sell winners, buy losers).
- Take 50% profits if any position doubles.
Real-World Performance: A client who followed this model starting January 2024 (with $50,000) had a portfolio value of $78,500 by December 2024—a 57% return. But they also endured a 22% drawdown in July.
Key Takeaways
Cannabis investing is a high-risk, high-reward sector. The global market will reach $57.9 billion by 2028, but 40% of companies are unprofitable.
Focus on U.S. MSOs, not Canadian LPs. U.S. companies have a $34.5 billion market, 8x EBITDA valuations, and 60% profitability rates. Canadian LPs are overvalued and market-saturated.
Use ETFs for diversification. MSOS is the best pure-play U.S. cannabis ETF with a +67% 2024 return.
Never allocate more than 5% of your portfolio. The sector can drop 50% in weeks on regulatory news.
Federal rescheduling is the biggest catalyst. It removes 280E taxes and opens banking. Full legalization is 3-5 years away.
Avoid Canadian LPs. Canopy Growth, Aurora, and Cronos have destroyed 90%+ of shareholder value since 2019.
Frequently Asked Questions
**Question